Artemisinin Resistance In Malaria Treated With IV Artesunate

Malaria Clinical Trial

— ARIMTIA  

Official title:

A Multicenter, Prospective, Observational Study to Assess the Efficacy of Artesunate in Malaria Treated With Parenteral Artesunate in Areas With Artemisinin Resistance A Study by the Tracking Resistance to Artemisinin Collaboration (TRAC)

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02640495
• Other study ID #: BAKMAL1504
• Status: Withdrawn
• Start date: October 2015
• Est. completion date: December 2017

Study information

• Verified date: August 2018
• Source: University of Oxford
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The spread of artemisinin resistant falciparum malaria presents new challenges to both the control and treatment of malaria. Loss of ring stage susceptibility to the artemisinins might jeopardize the use of parenteral artesunate as the first line drug for the treatment of severe falciparum malaria.

The purpose of this study is to assess the effect of artemisinin resistance (defined by a Kelch13 mutation with known functional significance) in P. falciparum malaria requiring parenteral artesunate treatment on lactate clearance parameters.

Description:

The investigators propose a multi-center observational study to assess the effect of artemisinin resistance (as defined by the presence of relevant Kelch13 mutations) on the efficacy of parenteral artesunate for the treatment of malaria, stratified for disease severity on admission.

The patients will receive the standard intravenous treatment for severe malaria (parenteral artesunate). Primary endpoints will be the plasma lactate concentration at 12 hours as a proportion of the plasma lactate at the start of treatment. Secondary endpoints will be improvement of Glasgow or Blantyre Coma Scores and other indicators of neurological recovery or deterioration, parasite clearance rates, time until resolution of fever, development of new severity or neurological signs under treatment, development of severe anemia, renal and hepatic injury, total duration of hospitalization , outcome of pregnancy in pregnant female patients, mortality rates and the necessity to treat with antibiotics, need for renal replacement therapy, mechanical ventilation, blood transfusion and rescue treatments.

On admission blood will be taken for the determination of genetic markers of antimalarial resistance (including Kelch13 mutations of known functional significance) and in vitro sensitivity tests to artemisinins and other antimalarials. Additional blood samples will be used for measuring plasma organic acid biomarkers of severe falciparum malaria measured by mass spectrometry. Difference in the kinetics of these acids will be an additional endpoint. Difference in the transcriptome of p. falciparum will be assessed by RNA measurements at baseline and 3 timepoints during treatment.

The proposed sites in Vietnam and Cambodia have been chosen based on the prevalence of artemisinin resistant falciparum malaria, incidence of severe malaria and local experience in participating in clinical trials.

Interim analysis:

To ensure timely recognition of the effect of artemisinin resistance on the outcome in malaria treated with parenteral artesunate, an interim analysis will be performed after the inclusion of 60 patients or one malaria transmission season (whatever comes first). An independent Data Safety Board will assess whether the difference in outcome between infections with artemisinin resistant versus sensitive strains warrants early termination and reporting of the study.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: December 2017
• Est. primary completion date: December 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Months and older

Eligibility

Inclusion Criteria:

• Male or female, aged over 6 months old

• Acute severe P. falciparum malaria or another indication to treat with IV artesunate. Defined as one or more of the following, occurring in the absence of an identified alternative cause, and in the presence of P. falciparum asexual parasitaemia:

• Prostration OR obtundation

• BCS<3 (preverbal children) or GCS<11 (adults)

• Convulsion in last 24 hours

• Suspected acidosis, manifesting as acidotic breathing

• Respiratory distress manifesting clinically (nasal flaring/indrawing) or oxygen saturation <92% or respiratory rate >30/min

• History of anuria

• Jaundice and/or hemoglobinuria

• Hemoglobin <7 g/dl or hematocrit <20%

• Significant bleeding including recurrent or prolonged bleeding from nose gums or venipuncture sites; hematemesis or melena

• Shock defined as systolic blood pressure <70 mm Hg (children) OR <80 mm Hg (adults)

• P. falciparum parasitaemia >10%

• Indication for parenteral antimalarial treatment (as assessed by clinician) other than nausea and vomiting. These may include laboratory findings such as:

• Creatinine >2.5 mg/dL (>220uM/L) or blood urea >56mg/dL (>20 mM/L)

• Glucose <4.0 mmol/L (<72mg/dL)

• Bilirubin > 3 mg/dL (>50uM/L)

• Hemoglobin <7g/dL or Hematocrit <20%

• P. falciparum parasitaemia >4%

• Venous plasma lactate >5 mM, Base deficit of >8meq/L or bicarbonate <15mM

• Written informed consent or consent by locally accepted representative in the case of patients rendered incapable of providing consent due to illness

Exclusion Criteria:

• History of 2 or more doses of parenteral antimalarial treatment in the previous 24 hours

• History of allergy or known contraindication to artemisinins

Related Conditions & MeSH terms

• Malaria

Intervention

Drug:
• Intravenous Artesunate as part of standard medical practice
Intravenous Artesunate 2.4 mg/kg

Locations

Country	Name	City	State
n/a

Sponsors (3)

Lead Sponsor	Collaborator
University of Oxford	Mahidol Oxford Tropical Medicine Research Unit, Oxford University Clinical Research Unit, Vietnam

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Absolute reduction of lactate	Absolute reduction of lactate at 12 hours after the first artesunate treat-ment compared to baseline.	12 hours
Secondary	Time needed until a plasma lactate concentration <2 mmol/L		42 days
Secondary	Change in Glasgow Coma Score (GCS) or Blantyre Coma Score (BCS)	at 12 hours after initial treatment and coma recovery time defined as GCS>10 or BCS>3 and GCS=15 and BCS=5	12 hours
Secondary	Base excess clearance after 12 hours	Base excess clearance after 12 hours as proportion of the base excess at presentation	42 days
Secondary	Time until a base excess concentration = minus 2 mmol/L		42 days
Secondary	Time to resuming the ability to sit, eat, drink, stand unsupported and walk		42 days
Secondary	The parasite clearance half-life		48 hours
Secondary	The parasite clearance ratios at H28 and H48 compared to parasite count on admission		48 hours
Secondary	The parasite clearance time for parasite count to fall to 50%, 90% and 99% of initial parasite density		7 days
Secondary	Differences in transcriptome patterns between artemisinin resistant parasites and artemisinin sensitive parasites at baseline		H0
Secondary	Differences in transcriptome patterns between artemisinin resistant parasites and artemisinin sensitive parasites at H6		H6
Secondary	Differences in transcriptome patterns between artemisinin resistant parasites and artemisinin sensitive parasites at H12		H12
Secondary	Differences in transcriptome patterns between artemisinin resistant parasites and artemisinin sensitive parasites at H48		H48
Secondary	Time until resolution of fever	(time until tympanic temperature first <37.5 Celsius and below 37.5C for 24 h)	14 days
Secondary	Proportion of patients developing new malaria	Proportion of patients developing new malaria severity signs as defined in the 2014 WHO severe malaria guidelines	42 days
Secondary	Proportion of patients developing new neurological signs assessed by neurological examination during hospitalization		42 days
Secondary	Prevalence of neurological sequelae assessed by neurological examination at discharge		42 days
Secondary	Prevalence of neurological sequelae assessed by neurological examination at day 7		7 days
Secondary	Prevalence of neurological sequelae assessed by neurologicalexamination at day 14		14 days
Secondary	Prevalence of neurological sequelae assessed by neurological examination at day 28 if day 14 is abnormal		28 days
Secondary	Prevalence of neurological sequelae assessed by neurological examination at day 42 if day 28 is abnormal		42 days
Secondary	Severity of neurological sequelae assessed by neurological examination at discharge		42 days
Secondary	Severity of neurological sequelae assessed by neurological examination at day 7		7 days
Secondary	Severity of neurological sequelae assessed by neurological examination at day 14		14 days
Secondary	Severity of neurological sequelae assessed by neurological examination at day 28 if day 14 is abnormal		28 days
Secondary	Severity of neurological sequelae assessed by neurological examination at day 42 if day 28 is abnormal		42 days
Secondary	Proportion treated with quinine	as a rescue treatment, antibiotics, blood products, anticonvulsants, renal replacement therapy, mechanical ventilation therapy, vasopressive drugs and oxygen therapy	42 days
Secondary	In hospital mortality		42 days
Secondary	Day 7, 14 hemoglobin or hematocrit levels	and in addition at day 28 and 42 if abnormal at day 14 or day 28 respectively	42 days
Secondary	Creatinine levels daily	during the first four days and thereafter on day 7 and 14 and in addition on day 28 and 42 if abnormal on day 14 or day 28 respectively	42 days
Secondary	Bilirubin, Alanine transaminase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase levels daily	during the first four days and thereafter on day 7, 14 and in addition on day 28 and 42 if abnormal on day 14 or 28 respectively	42 days
Secondary	Plasma biomarkers of severe (artemisinin resistant) malaria		42 days
Secondary	outcome of pregnancy during hospitalization	If pregnant	42 days
Secondary	Time until discharge		42 days